Table 5 One-way sensitivity analysis
| Â | Treatment costs | Surveillance costs | Total costs | Pr (sarcoma death) | Life years | QALYs | ICER |
|---|---|---|---|---|---|---|---|
Scenario analyses designed favour surveillance strategies that detect only metastatic disease | |||||||
 No surveillance | $35,022 | $0 | $35,022 | 0.43 | 19.57 | 7.67 |  |
 Low freq. CT | $35,260 | $3184 | $38,444 | 0.41 | 20.07 | 7.81 | $24,483 |
 CT | $35,796 | $4031 | $39,827 | 0.40 | 20.33 | 7.89 | $16,335 |
 CT + MRI | $36,171 | $10,654 | $46,825 | 0.39 | 20.55 | 7.95 | $129,501 |
 PET | $36,056 | $25,566 | $61,622 | 0.39 | 20.52 | 7.93 | Dominated |
Scenario analyses designed favour surveillance strategies that detect local recurrence and metastatic disease | |||||||
 No surveillance | $49,864 | $0 | $49,864 | 0.43 | 19.57 | 7.25 |  |
 Low freq. CT | $51,885 | $3184 | $55,069 | 0.41 | 20.07 | 7.31 | $75,672 |
 CT | $52,810 | $4031 | $56,841 | 0.40 | 20.33 | 7.39 | $24,967 |
 CT + MRI | $52,113 | $10,654 | $62,766 | 0.39 | 20.55 | 7.47 | $72,755 |
 PET | $51,803 | $25,566 | $77,369 | 0.39 | 20.52 | 7.46 | Dominated |